Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerPrecision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal MedicineProteomics and peptidomics: moving toward precision medicine in urological malignanciesThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsIncorporation of tissue-based genomic biomarkers into localized prostate cancer clinicsQuantitative comparison and reproducibility of pathologist scoring and digital image analysis of estrogen receptor β2 immunohistochemistry in prostate cancer.How Precisely Can Prostate Cancer Be Managed?Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics dataProstate cancer proteomics: Current trends and future perspectives for biomarker discovery.Emerging proteomics biomarkers and prostate cancer burden in Africa.Proteomics in cancer biomarkers discovery: challenges and applications.Applying precision medicine to the active surveillance of prostate cancer.Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics.Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer.Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.Is There a Future for Chemoprevention of Prostate Cancer?Genomic tests to guide prostate cancer management following diagnosis.PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.Conditional probability of reclassification in an active surveillance program for prostate cancerComprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.Tissue-based biomarkers in prostate cancer.Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives.The Use of Biomarkers in Prostate Cancer Screening and Treatment.[Molecular biomarkers and prognostic factors for prostate cancer].Emerging biomarkers in the diagnosis of prostate cancer.Increased α-actinin-1 destabilizes E-cadherin-based adhesions and associates with poor prognosis in basal-like breast cancer.Genomic biomarkers in prostate cancerEntering an era of radiogenomics in prostate cancer risk stratificationSerum thymidine kinase 1 is associated with Gleason score of patients with prostate carcinoma
P2860
Q26738703-5C5D65FB-2BE2-41F5-AEEB-D00199A57308Q26741336-9BC377E3-78E9-443F-970B-4C6F3BA7D685Q26749401-1B15CC87-3BA1-46B9-B37D-9B5B5EF2FCD9Q26750672-EDC7BD46-FA4B-4006-8BBA-B3F881FAA55DQ26752510-B2C1E94D-3040-4D67-BEF7-EF7D6B726B0DQ27302276-38F44189-A4D2-494A-AC01-006666074C24Q28078942-2061DB37-9982-40D2-A777-CC6BBA041A25Q31070165-9087BE41-2259-4FD1-B19C-E04020A917C3Q33567004-8A14A37A-1C16-4C73-87FE-B28736EE80A4Q33914221-15F1C32D-7C8F-437E-8F93-38D52290DC0DQ35592114-584A8C48-752F-4C10-B742-4C6DF4CE86E6Q36592871-41203218-1314-4D9C-A870-CCB26CEDD820Q37029385-0FE2E41D-7F4F-4A56-9242-5AE6434AA15EQ38540198-A493C269-AA93-4047-93C9-683433F33A5AQ38709426-76A9EBF4-0D72-424F-8C74-9443244BDDACQ38780013-CE759331-B9E9-4DC2-B491-3F3BA6F03745Q38841717-C5397A5F-F418-4F54-BDD0-5D7F0623E2FBQ38878301-B7EBE2D8-8FB9-4902-9E34-765ABCCF3847Q39170943-16877B66-BF50-4E60-8A7D-511F39F2E0ACQ40738452-3611BB10-C678-4AB2-B083-E26984699FFFQ41495208-2B6E2866-6A33-450C-8714-3086C67B4A9DQ45977883-B3C915AA-565F-4D0A-B5D5-D8C4EB03517FQ47110549-EF656670-2CED-4215-A7F5-DE251F9C7A2EQ47144748-4C1E5799-110C-492B-ACDA-F778AF8F4F20Q47282493-ABC6380A-9D55-406B-9AD2-52DA561EFE31Q52689045-0A31B0AE-614E-4699-8408-76566B193487Q53251387-CBDAE29D-67D9-4965-9A44-FB697F576469Q54964875-D15E86EB-62FC-4ACD-B5E3-8065B9A82126Q55307144-A35BEC10-EB6E-48C0-9E3F-C291D67486FCQ57112354-92CBF6A1-DB22-49CA-ADF0-F2CE8DB07D5DQ58562049-F4AE32D0-4E73-46B4-AB8A-7D75543F79B5Q58573232-451F7495-BF68-4FFC-A451-7412089250F9
P2860
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Identification of proteomic bi ...... despite biopsy-sampling error.
@ast
Identification of proteomic bi ...... despite biopsy-sampling error.
@en
type
label
Identification of proteomic bi ...... despite biopsy-sampling error.
@ast
Identification of proteomic bi ...... despite biopsy-sampling error.
@en
prefLabel
Identification of proteomic bi ...... despite biopsy-sampling error.
@ast
Identification of proteomic bi ...... despite biopsy-sampling error.
@en
P2093
P2860
P356
P1476
Identification of proteomic bi ...... despite biopsy-sampling error
@en
P2093
A D Hurley
M Shipitsin
P2860
P2888
P304
P356
10.1038/BJC.2014.396
P407
P50
P577
2014-07-17T00:00:00Z